Modulating the gut microbiota and inflammation is involved in the effect of diosgenin against diabetic nephropathy in rat
DIO is a multitarget agent that addresses both gut microbiota homeostasis and NLRP3-driven inflammation, presenting a novel therapeutic strategy for DN through modulation of the gut-kidney axis.
Authors
- Pan Shu (ORCID: https://orcid.org/0000-0002-9768-3498)
- Jiang Shanshan
- Hao Zhu (ORCID: https://orcid.org/0000-0003-4138-5624)
- Xiao Hu (ORCID: https://orcid.org/0000-0003-1128-4099)
- Yuan Yong-fang
- Kudelaidi Kuerban
- Yujie Wang (ORCID: https://orcid.org/0009-0007-4224-079X)
- Rong Wang (ORCID: https://orcid.org/0000-0002-5108-3286)
- Shi Yuhuan
Institutions
- Tongji University (CN)
- Shanghai Jiao Tong University (CN)
- Shanghai Ninth People's Hospital (CN)
- Tongji Hospital (CN)
- Shanghai Institute of Pharmaceutical Industry (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-05-19
- DOI
- https://doi.org/10.3389/fphar.2025.1555849
- Citations
- 1
- Primary Topic
- Gut microbiota and health
- Type
- article
- Field-Weighted Citation Impact
- 0.81
Funders
- Shanghai Jiao Tong University
- School of Medicine, Shanghai Jiao Tong University